| 000 | 02617 a2200673 4500 | ||
|---|---|---|---|
| 005 | 20250516121225.0 | ||
| 264 | 0 | _c20130107 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1097-6744 | ||
| 024 | 7 |
_a10.1016/j.ahj.2012.08.010 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDiletti, Roberto | |
| 245 | 0 | 0 |
_aABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. _h[electronic resource] |
| 260 |
_bAmerican heart journal _cNov 2012 |
||
| 300 |
_a654-63 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 |
_aAbsorbable Implants _xadverse effects |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAspirin _xadministration & dosage |
| 650 | 0 | 4 | _aCoronary Angiography |
| 650 | 0 | 4 |
_aCoronary Artery Disease _xcomplications |
| 650 | 0 | 4 |
_aCoronary Thrombosis _xetiology |
| 650 | 0 | 4 |
_aDrug-Eluting Stents _xadverse effects |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aEverolimus |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyocardial Ischemia _xdrug therapy |
| 650 | 0 | 4 | _aNew Zealand |
| 650 | 0 | 4 |
_aPiperazines _xadministration & dosage |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aPrasugrel Hydrochloride |
| 650 | 0 | 4 | _aResearch Design |
| 650 | 0 | 4 | _aSample Size |
| 650 | 0 | 4 | _aSingle-Blind Method |
| 650 | 0 | 4 |
_aSirolimus _xanalogs & derivatives |
| 650 | 0 | 4 | _aSpectroscopy, Near-Infrared |
| 650 | 0 | 4 |
_aThiophenes _xadministration & dosage |
| 650 | 0 | 4 |
_aTissue Scaffolds _xadverse effects |
| 650 | 0 | 4 | _aTomography, X-Ray Computed |
| 650 | 0 | 4 | _aUltrasonography, Interventional |
| 700 | 1 | _aSerruys, Patrick W | |
| 700 | 1 | _aFarooq, Vasim | |
| 700 | 1 | _aSudhir, Krishnankutty | |
| 700 | 1 | _aDorange, Cecile | |
| 700 | 1 | _aMiquel-Hebert, Karine | |
| 700 | 1 | _aVeldhof, Susan | |
| 700 | 1 | _aRapoza, Richard | |
| 700 | 1 | _aOnuma, Yoshinobu | |
| 700 | 1 | _aGarcia-Garcia, Hector M | |
| 700 | 1 | _aChevalier, Bernard | |
| 773 | 0 |
_tAmerican heart journal _gvol. 164 _gno. 5 _gp. 654-63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ahj.2012.08.010 _zAvailable from publisher's website |
| 999 |
_c22250169 _d22250169 |
||